

<i>Technology appraisal (TA)</i>	<i>Date of TA Release</i>	<i>Adherence of local formulary to NICE</i>	
		<i>Included on the Trust Formulary for this indication Yes OR No</i>	<i>Reason provided if "No"</i>
<b>2018-19</b>			
<a href="#">TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma</a>	17/10/2018	<b>Yes</b>	
<a href="#">TA543 - Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs</a>	03/10/2018	<b>Yes</b>	
<a href="#">TA542 - Cabozantinib for untreated advanced renal cell carcinoma</a>	03/10/2018	<b>Yes</b>	
<a href="#">TA541 - Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia</a>	19/09/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma</a>	03/09/2018	<b>Yes</b>	
<a href="#">TA539 - Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours</a>	29/08/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA538 - Dinutuximab beta for treating neuroblastoma</a>	22/08/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA537 - Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	08/08/2018	<b>Yes</b>	
<a href="#">TA536 - Alectinib for untreated ALK-positive advanced non-small-cell lung cancer</a>	08/08/2018	<b>Yes</b>	
<a href="#">TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine</a>	08/08/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA534 - Dupilumab for treating moderate to severe atopic dermatitis</a>	01/08/2018	<b>Yes</b>	
<a href="#">TA533 - Ocrelizumab for treating relapsing–remitting multiple sclerosis</a>	25/07/2018	<b>No</b>	Not applicable to CWFT - Specialist Centres only and CWFT is not a commissioning Centre
<a href="#">TA532 - Cenegelein for treating neurotrophic keratitis</a>	18/07/2018	<b>No</b>	Not recommended
<a href="#">TA531 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer</a>	18/07/2018	<b>Yes</b>	
<a href="#">TA530 - Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy</a>	04/07/2018	<b>No</b>	Not recommended
<a href="#">TA529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer</a>	04/07/2018	<b>Yes</b>	
<a href="#">TA528 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer</a>	04/07/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA527 - Beta interferons and glatiramer acetate for treating multiple sclerosis</a>	27/06/2018	<b>Yes</b>	
<a href="#">TA526 - Arsenic trioxide for treating acute promyelocytic leukaemia</a>	13/06/2018	<b>No</b>	Not applicable to CWFT - Condition not treated at CWFT
<a href="#">TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</a>	13/06/2018	<b>Yes</b>	
<a href="#">TA524 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma</a>	13/06/2018	<b>Yes</b>	
<a href="#">TA523 - Midostaurin for untreated acute myeloid leukaemia</a>	13/06/2018	<b>No</b>	Not applicable to CWFT - Specialist Centres only and CWFT is not a commissioning Centre
<a href="#">TA522 - Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable</a>	13/06/2018	<b>Yes</b>	
<a href="#">TA521 - Guselkumab for treating moderate to severe plaque psoriasis</a>	13/06/2018	<b>Yes</b>	
<a href="#">TA520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy</a>	16/05/2018	<b>Yes</b>	
<a href="#">TA519 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</a>	25/04/2018	<b>Yes</b>	
<a href="#">TA518 - Tocilizumab for treating giant cell arteritis</a>	18/04/2018	<b>No</b>	Not applicable to CWFT - Specialist Centres only and CWFT is not a commissioning Centre
<a href="#">TA517 - Avelumab for treating metastatic Merkel cell carcinoma</a>	11/04/2018	<b>Yes</b>	